BiotechTube

belapectin + Placebo

Phase 2/3Terminated
0 views this week 0 watching💤 Quiet
Interest: 20/100
20
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prevention of Esophageal Varices

Conditions

Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis

Trial Timeline

Jun 25, 2020 → Apr 10, 2025

NCT ID
NCT04365868

About belapectin + Placebo

belapectin + Placebo is a phase 2/3 stage product being developed by Galectin Therapeutics for Prevention of Esophageal Varices. The current trial status is terminated. This product is registered under clinical trial identifier NCT04365868. Target conditions include Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis.

What happened to similar drugs?

9 of 20 similar drugs in Prevention of Esophageal Varices were approved

Approved (9) Terminated (0) Active (11)
✅RaltegravirMerckApproved
✅Meningococcal C conjugate vaccineNovartisApproved
✅Meningococcal C conjugate vaccineNovartisApproved
✅Boostrix + Placebo (Saline)NovartisApproved
✅Meningococcal C conjugate vaccineNovartisApproved
✅Lenacapavir long-actingGilead SciencesApproved
✅DescovyGilead SciencesApproved

Hype Score Breakdown

Clinical
15
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04365868Phase 2/3Terminated

Competing Products

20 competing products in Prevention of Esophageal Varices

See all competitors
ProductCompanyStageHype Score
mRNA-1944ModernaPhase 1
0
Gam-COVID-VacDr. Reddy's LaboratoriesPhase 2/3
31
edoxaban + enoxaparin sodiumDaiichi SankyoPhase 3
40
MifepristoneEli LillyPhase 2
35
EXANTAAstraZenecaPhase 2
27
Risk of low dose aspirin discontinuationAstraZenecaPre-clinical
26
DAPA/MET XR + DAPA + MET XRAstraZenecaPhase 3
40
Esomeprazole + PlaceboAstraZenecaPhase 3
40
PCV15MerckPre-clinical
18
RaltegravirMerckApproved
43
RotaTeq (V260) + IPVMerckPhase 3
40
V501MerckPhase 3
40
ZostavaxMerckPhase 3
40
V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920MerckPhase 3
40
Letermovir + PlaceboMerckPhase 3
40
Meningococcal C conjugate vaccineNovartisApproved
43
Enteric-coated mycophenolate sodiumNovartisPhase 3
40
Meningococcal C conjugate vaccineNovartisApproved
43
rMenB+OMV NZNovartisPhase 3
40
Enteric-Coated Mycophenolate SodiumNovartisPhase 3
40